# Childhood Immunization Schedules and Catch-Up Strategies
## Overview
Childhood immunization is one of the most effective public health interventions in history. Family physicians must be proficient in the recommended ACIP schedule, catch-up protocols for under-immunized children, contraindication assessment, and evidence-based strategies for counseling vaccine-hesitant families.
## Routine Immunization Schedule (ACIP 2025)
| Age | Vaccines Administered |
|-----|----------------------|
| Birth | HepB #1 |
| 2 months | DTaP #1, IPV #1, Hib #1, PCV #1, RV #1, HepB #2 |
| 4 months | DTaP #2, IPV #2, Hib #2, PCV #2, RV #2 |
| 6 months | DTaP #3, PCV #3, RV #3 (RotaTeq), HepB #3 (6-18 mo), Influenza (annual from 6 mo) |
| 12-15 months | MMR #1, Varicella #1, Hib booster, PCV booster, HepA #1 |
| 15-18 months | DTaP #4 |
| 4-6 years | DTaP #5, IPV #4, MMR #2, Varicella #2 |
| 11-12 years | Tdap, HPV (2- or 3-dose series), MenACWY #1 |
| 16 years | MenACWY booster |
### Birth
Hepatitis B vaccine should be administered as the first dose within 24 hours of birth using the monovalent formulation. Infants born to HBsAg-positive mothers should receive both the HepB vaccine and hepatitis B immune globulin within 12 hours of birth.
### 2 Months
At 2 months, the first doses of DTaP (diphtheria, tetanus, and acellular pertussis), IPV (inactivated polio), Hib (Haemophilus influenzae type b), PCV15 or PCV20 (pneumococcal conjugate), and rotavirus are administered. Rotavirus comes in two formulations: RV1 (Rotarix) as a 2-dose series and RV5 (RotaTeq) as a 3-dose series. The second dose of HepB is also given at this visit.
### 4 Months
The second doses of DTaP, IPV, Hib, PCV, and rotavirus are administered at 4 months.
### 6 Months
At 6 months, the third doses of DTaP and PCV are given, along with the third rotavirus dose if using RV5. The third HepB dose can be administered between 6 and 18 months. Influenza vaccination begins at 6 months, with 2 doses in the first season followed by 1 dose annually.
### 12-15 Months
The first doses of MMR (measles, mumps, rubella) and varicella are given at 12 to 15 months, along with the Hib booster (dose 3 or 4 depending on the product), the PCV booster, and the first dose of HepA (hepatitis A), which is given between 12 and 23 months with the second dose at least 6 months later.
### 15-18 Months
The fourth dose of DTaP is administered between 15 and 18 months.
### 4-6 Years
At 4 to 6 years, the fifth dose of DTaP, fourth dose of IPV, second dose of MMR, and second dose of varicella are given.
### 11-12 Years
At 11 to 12 years, a single dose of Tdap replaces the DTaP booster. The HPV vaccine is started as a 2-dose series if initiated before age 15 or a 3-dose series if starting at age 15 or later. The first dose of MenACWY (meningococcal conjugate) is given with a booster at age 16. MenB (meningococcal serogroup B) is available through shared clinical decision-making for ages 16 to 23, with a preferred window of 16 to 18.
### 16 Years
The MenACWY booster is administered at age 16.
## Minimum Intervals and Ages
Each vaccine has a minimum age for the first dose and minimum intervals between subsequent doses. Doses administered before the minimum age or interval are not counted and must be repeated. Key minimum ages include 6 weeks for DTaP and IPV, and 12 months for MMR, varicella, and HepA. Key minimum intervals include 4 weeks between DTaP doses 1 through 3, 6 months between dose 3 and 4, 4 weeks between MMR dose 1 and 2, 4 weeks between HepB dose 1 and 2, and 8 weeks between HepB dose 2 and 3 (with at least 16 weeks from dose 1 to dose 3).
## Catch-Up Immunization
### General Principles
A vaccine series should never be restarted regardless of the time elapsed between doses. All age-appropriate vaccines should be given simultaneously at different anatomical sites. The ACIP catch-up schedule should be used to determine minimum intervals. Vaccine history should be documented carefully, and if records are unavailable, serologic testing or revaccination should be considered.
### Catch-Up by Vaccine
#### HepB
The 3-dose series can be completed at any age. An accelerated schedule of 0, 1, and 2 months with a booster at 12 months is available. For adults 18 and older, Heplisav-B offers a 2-dose series given 1 month apart.
#### DTaP/Tdap
Children under 7 should complete the DTaP series with appropriate intervals. Children aged 7 and older who never received DTaP should receive one dose of Tdap followed by Td or Tdap to complete the series. Minimum intervals are 4 weeks between doses 1 through 3, and 6 months between dose 3 and 4 and between dose 4 and 5.
#### IPV
The 4-dose series requires that the final dose be given at age 4 years or older regardless of previous doses. Adults who completed the series in childhood need only a single lifetime booster if traveling to an endemic area.
#### MMR
Two doses are needed with a minimum interval of 4 weeks. The vaccine can be given as early as 6 months for international travel, though a dose given before 12 months does not count toward the series. Measles immunity is established by documented receipt of 2 doses of MMR, laboratory evidence of immunity, or birth before 1957.
#### Varicella
Two doses are required, with a minimum interval of 3 months if the child is under 13 and 4 weeks if 13 or older. Evidence of immunity includes documented disease, receipt of 2 doses, positive titer, or birth in the United States before 1980.
#### Hib
Catch-up dosing depends on the age at which the first dose was given. Hib vaccination is generally not needed after age 5 unless the patient has asplenia or is immunocompromised.
## Combination Vaccines
Several combination vaccines reduce injection burden. Pediarix combines DTaP, IPV, and HepB. Pentacel combines DTaP, IPV, and Hib. Vaxelis combines DTaP, IPV, HepB, and Hib. MMRV (ProQuad) combines MMR and varicella but should be used with caution as dose 1 in children aged 12 to 23 months due to a higher risk of febrile seizure compared to separate MMR and varicella injections. Twinrix combines HepA and HepB for adults. Combination vaccines reduce injection burden but cannot be used to extend minimum ages or intervals beyond the requirements of their individual components.
## Contraindications and Precautions
### True Contraindications
True contraindications include severe allergic reaction (anaphylaxis) to a prior dose or vaccine component. MMR and varicella are contraindicated in pregnancy and severe immunodeficiency, though not in HIV with a CD4 count of 200 or above. Rotavirus is contraindicated with a history of intussusception or severe combined immunodeficiency. LAIV (live attenuated influenza vaccine) is contraindicated in pregnancy, immunocompromised individuals, children on aspirin therapy, and those under age 2 or over age 49. DTaP is contraindicated when encephalopathy occurred within 7 days of a prior dose, in which case DT should be substituted.
### Common Precautions (NOT Contraindications)
Precautions include moderate to severe acute illness (defer until improved), recent blood product administration (defer live vaccines for 3 to 11 months depending on the product), and a history of Guillain-Barre syndrome within 6 weeks of a prior dose (relevant to influenza and Tdap).
### NOT Contraindications (Common Misconceptions)
Conditions frequently but incorrectly perceived as contraindications include mild illness with or without fever, current antibiotic use, prematurity (vaccinate on chronologic age schedule except for HepB in infants under 2 kg), breastfeeding, family history of adverse reactions, egg allergy (MMR, varicella, and influenza are all safe), and a history of prior local reactions.
## Special Populations
Preterm infants should be vaccinated on chronologic age. HepB should be given at birth if birth weight is 2 kg or above; if below 2 kg, the dose is delayed until 1 month of age or hospital discharge. Immunocompromised children should avoid live vaccines (MMR, varicella, LAIV, and rotavirus), though inactivated vaccines are safe but may have reduced efficacy. IDSA guidelines should be consulted for specific guidance. Children with asplenia require vaccination with PCV, PPSV23, MenACWY, MenB, and Hib. Children with HIV can receive MMR and varicella if the CD4 count is 200 or above (or 15% or above in children under 5).
## Addressing Vaccine Hesitancy
### Understanding Concerns
Common parental concerns include safety fears (the debunked autism myth, the "too many too soon" argument, and concerns about ingredients such as thimerosal and aluminum), preference for natural immunity, religious or philosophical objections, distrust of pharmaceutical companies or government, and misinformation from social media and anti-vaccine websites.
### Evidence-Based Counseling Strategies
The presumptive approach, stating "Today we will be giving the 2-month vaccines," is more effective than the participatory approach of asking whether the parent would like to vaccinate. Motivational interviewing allows the clinician to explore concerns non-judgmentally, express empathy, and provide tailored information. Specific concerns should be acknowledged and addressed with clear, evidence-based responses. Regarding MMR and autism, the Wakefield study was retracted, and multiple large studies involving over 1 million children show no association. Thimerosal was removed from childhood vaccines since 2001 (except multi-dose flu), and no evidence of harm exists. The "too many" argument is countered by the fact that children's immune systems handle thousands of antigens daily, and vaccine antigens represent a tiny fraction. The amounts of aluminum and formaldehyde in vaccines are far below daily natural exposure levels. Sharing a personal recommendation, such as "I vaccinate my own children and strongly recommend vaccines for your child," carries significant influence. CDC Vaccine Information Statements are required by law before each vaccination and serve as useful visual aids.
### Alternative Schedules
No evidence supports delayed or alternative vaccination schedules. Delayed vaccination leaves children vulnerable during the highest-risk period. If a family insists on modification, the clinician should prioritize vaccines with the highest disease burden for the child's age, continue the dialogue at subsequent visits, and document the discussion.
### Practice Policies
Some practices dismiss vaccine-refusing families, but the AAP recommends against dismissal in order to maintain a medical home. All counseling and refusals should be documented using the AAP refusal-to-vaccinate form.
## Vaccine Storage and Administration
Refrigerator vaccines are stored at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Freezer vaccines, including LAIV, varicella, zoster, and MMR, are stored at minus 50 to minus 15 degrees Celsius. Temperature should be monitored with digital data loggers, and excursions should be reported to the manufacturer. Intramuscular injection sites include the vastus lateralis for infants under 12 months and the deltoid for toddlers and older children. Subcutaneous injections (MMR, varicella, IPV) are given in the fatty tissue of the thigh or upper arm. Correct needle length is 1 inch (25 mm) for IM injections in infants and 1 to 1.25 inches for older children.
The ACIP recommended childhood immunization schedule from birth through 18 years displayed as a color-coded timeline grid showing each vaccine, the recommended ages for each dose, catch-up age ranges, and footnotes for special populations including immunocompromised children and those with specific medical conditions.
A catch-up immunization decision flowchart showing the step-by-step process for evaluating an under-immunized child: determining current age, reviewing documented doses, identifying minimum intervals for remaining doses, prioritizing vaccines based on disease risk, and scheduling visits to complete the series as rapidly as possible.
A visual guide for vaccine administration showing correct needle gauge and length by age group, anatomical injection sites (vastus lateralis for infants, deltoid for older children), proper technique for intramuscular and subcutaneous routes, and maximum number of injections per site visit with spacing recommendations for multiple simultaneous injections.
## Clinical Pearls
A vaccine series should never be restarted regardless of how much time has passed between doses; the clinician should simply pick up where the series left off. The presumptive approach of stating that vaccines will be given today is more effective than the participatory approach of asking whether the parent would like to vaccinate for routine childhood vaccines. Egg allergy, even when severe, is not a contraindication to MMR, varicella, or influenza vaccines, and these can be given safely in the primary care office. MMRV as dose 1 in children 12 to 23 months carries a slightly higher risk of febrile seizure compared to separate MMR and varicella; this should be discussed with parents, or separate injections should be used. Prematurity is not a reason to delay vaccination; chronologic age rather than gestational age determines the schedule, with the exception of HepB in infants under 2 kg at birth. Rotavirus vaccine has strict maximum age limits for administration: dose 1 must be given by 14 weeks and 6 days, and the final dose by 8 months and 0 days, with no administration possible after these windows. Documentation of vaccine refusal is essential using the AAP refusal-to-vaccinate form, and vaccines should continue to be offered at subsequent visits. Simultaneous administration of all age-appropriate vaccines is safe, effective, and recommended; there is no immunologic basis for spacing out vaccines.
## References
- ACIP Recommended Child and Adolescent Immunization Schedule. CDC. 2025
- Opel DJ et al. The Architecture of Provider-Parent Vaccine Discussions. Pediatrics. 2013
- Kroger A et al. General Best Practice Guidelines for Immunization. CDC. 2023
- AAP Committee on Infectious Diseases. Red Book: Report of the Committee on Infectious Diseases. 33rd ed. 2024
- Hviid A et al. Measles, Mumps, Rubella Vaccination and Autism. Ann Intern Med. 2019